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Two distinct binding sites for globotriaosyl ceram ide on verotoxins: 
identification by molecular modelling and confirmation using deoxy 
analogues and a new glycolipid receptor for all verotoxins 
Per-Georg Nyholm’ , G&an Magnusson*, Zhiyuan Zheng*, Raquel Nore13, 
Beth Binnington-Boyd4 and Clifford A  Lingwood415 
Background: The Escherichia co/i verotoxins (VTs) can initiate human vascular 
disease via the specific recognition of globotriaosyl-ceramide (Gb,) on target 
endothelial cells. To explore the structural basis for receptor recognition by 
different VTs we used molecular modell ing based on the crystal structure of VT1 , 
mutational data and binding data for deoxy galabiosyl receptors. 
Results: We propose a model for the verotoxin ‘cleft-site complex’ with Gb,. 
Energy minimizations of Gb, within the ‘cleft site’ of verotoxins VT1 , VT2, VT2c 
and VT2e resulted in stable complexes with hydrogen-bonding systems that 
were in agreement with binding data obtained for mono-deoxy analogues of Gb,. 
N-deacetylated globoside (aminoGb,), which was found to be a new, efficient 
receptor for all verotoxins, can be favorably accommodated in the cleft site of the 
VTs by formation of a salt bridge between the galactosamine and a cluster of 
aspat-tates in the site. The model is further extended to explain the binding of 
globoside by VT2e. Docking data support the possibility of an additional binding 
site for Gb, on VT1 . 
Conclusions: The proposed models for the complexes of verotoxins with their 
globoglycolipid receptors are consistent with receptor analogue binding data 
and explain previously published mutational studies. The results provide a first 
approach to the design of specific inhibitors of VT-receptor binding. 
Introduction 
Verotoxins (VTs) are Escherichia coli subunit toxins com- 
prising a single -30 kDa A-subunit, which has N-glyca- 
nase activity [l] and is responsible for inhibition of 
protein synthesis, and five noncovalently associated 
7.5 kDa receptor-binding B-subunits [2,3]. The family of 
verotoxins includes VTl, VT2 and VT%, all of which are 
implicated in the microvascular pathologies hemorrhagic 
colitis and hemolytic uremic syndrome (HUS) [4] and 
bind to globotriaosylceramide (Gbs: galal-4galpl-4glc 
ceramide). The remaining verotoxin, VT’Ze (the pig 
edema disease toxin [5,6]), binds to Gb, and globo- 
tetraosyl ceramide (Gb4: galNAcpl-3galal-4gaIpl-4glc 
ceramide) [7]. There is a high incidence of HUS in 
children following gastrointestinal infection with 
verotoxin-producing E. co& this correlates with the 
selective expression of Gb, in the pediatric renal 
glomerulus [8]. Thus it is likely that the epidemiology of 
this disease is determined by receptor distribution [9]. It 
has been suggested that oral administration of matrix- 
bound Gb, oligosaccharide within the gastrointestinal 
tract may provide a novel means of reducing the 
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incidence or severity of HUS symptoms by reducing VT 
translocation into the circulation [lo]. 
Cultured endothelial cells can be verotoxin sensitive 
[ll,lZ], and their sensitivity can be modulated by cyto- 
kines [13-171. Gb, is also a human B-cell’differentiation 
antigen [l&19], involved in signal transduction through the 
o12-interferon receptor [ZO-221 and CD19 [23], both of 
which contain a VT1 B-subunit-like binding site for Gb, 
[24,25]. B-subunit binding to Gbs-positive B-lymphocytes 
results in the induction of apoptosis [26], and verotoxin 
binding abrogates B-cell function in vitro [27]. A similar 
induction of apoptosis is seen after holotoxin treatment of 
vero [28] and astrocytoma (S. Arab eta& unpublished data) 
cells, and the increased Gb, synthesis of certain human 
tumours renders them sensitive to verotoxin killing in vitro 
and in viva ([29], S. Arab eta/., unpublished data). 
Thus, defining the molecular basis of Gb, recognition by 
the B-subunit pentamer will be important to understand 
the basis of human vascular disease and B-cell differ- 
entiation, and to develop neoplastic therapies. Although 
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the crystal structure of the verotoxin B-subunit pentamer 
[30] and holotoxin [31] have been determined, it is 
probable that solubility problems will prevent the co- 
crystallization of verotoxin with its receptor glycolipid. The 
toxin does not bind [32,33], or binds very poorly [34], to 
the free oligosaccharide moiety from Gb, (Kd - 10” M, as 
compared to K, - 10m9 M  for Gb,). We have therefore used 
a combination of theoretical calculation and experimental 
binding to glycolipid receptor analogues to predict the 
precise location of the Gb, binding site within the known 
crystal structure of the VT1 B-subunit. In a preliminary 
report [35], we proposed a model of the Gb,-VT1 
B-subunit complex in which the galal-4gal moiety is 
docked into a crevice close to the interface between 
adjacent B-subunits (site I or the ‘cleft site’). Here we 
show that N-deacetylated Gb, (aminoGbJ is a new, 
efficient receptor for all VTs that is well accommodated in 
the cleft site. We extend our model to explain the binding 
of Gb, by the various natural VTs, and the additional 
binding of Gb, by VTZe. We also define a second potential 
carbohydrate binding site on the verotoxin B-subunit that 
may be more important in the binding of Gb, by the other 
members of the verotoxin family, particularly VT& 
binding to Gb, that contains a Cl8 fatty acid [36]. 
Results 
Binding of aminoGb, 
Although Gb, is the preferred receptor for VTZe, this 
glycolipid is not recognized above background by VTl, 
VT2 or VT& (Fig. 1). Selective deacetylation of the 
terminal galNAc residue by basic hydrolysis, as previously 
described [37], generates a glycolipid that is avidly bound 
by all members of the verotoxin family (Figs 1,2). By thin- 
layer chromatography overlay, the binding of VT1 and 
VTZe to aminoGb4 is approximately equivalent to their 
binding to Gb, and Gb,, respectively, whereas VT2 and 
VTZc bind aminoGb4 preferentially (Fig. 1). In the 
microtitre assay, aminoGb4 is as effective as the pre- 
ferred receptor for each toxin (Fig. 2). Binding to the 
N-dimethylated derivative of aminoGb4 was as effective 
as binding to aminoGb4 (data not shown). Thus, toxin 
binding was probably facilitated by the deacetylation of 
Gb, because of the generation of charge on the amine, not 
Figure 1 
by the steric effect of the loss of the acetyl group. The 
charge by itself is insufficient to confer binding, however, 
since similarly N-deacetylated gangliotriaosyl ceramide 
[37] was not bound (data not shown). 
Modell ing of the VTl-aminoGb, complex 
Calculations of electrostatic potentials were performed on 
the VT1 B-subunits using the Delphi program to locate 
favourable binding sites for an NH,+ function. A major 
domain of negative potential is contained within the 
previously described site I (‘cleft site’) [35] for binding of 
the carbohydrate moiety of Gb, (see Supplementary 
material and [35]). This negative potential is mainly due 
to an Asp triplet (Aspl6-Aspl7-Aspl8) located in a loop at 
the interface between adjacent subunits. The corresp- 
onding Delphi calculations on aminoGb4 (see Suppl- 
ementary material) reveals a complementary positive 
region, comprising the NH,+ group and a positively 
charged patch, extending across the ol-galactose to the 
hydrophobic face of the B-galactose moiety. 
Modelling of aminoGb4 in site I based on our previous 
model of the VTl-Gb, complex placed the NH,’ group of 
galactosamine close enough to the Asp triplet to form a salt 
bridge with the carboxyl of Asp16 (Fig. 3a). This carboxyl 
group is also the acceptor for a hydrogen bond from the 
3-OH group of the galactosamine. In addition, two hydro- 
gen bonds were established between the galactosamine 
4-OH group and the amino-terminal Thrl of the adjacent 
subunit. The globotriaose portion of aminoGb4. formed 
seven hydrogen bonds with the protein (Table 1, Fig. 3a,b). 
These interactions are also present in the proposed model 
of the VT1 site I-Gb, complex (Fig. 3d). The hydrogen 
bonding system is shown schematically in Figure 3b. 
The curvature of the galal-4gal moiety is sterically 
complementary to the crevice lined by Phe30, Thdl and 
Asnl5 in site I. A 90” projection of the complex (Fig. 3c) 
shows that the gal&l-4gal moiety is snugly accommodated. 
The conformation of aminoGb4 in the complex is almost 
identical to the minimum energy conformation of unbound 
aminoGb4 as calculated with GESA and Discover (Table 2; 
for details see Materials and methods). The conformation 
w k-J) 63) 
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1231 12341234 1234 
AminoGb, binds to all members of the 
verotoxin family. The figure shows a thin-layer 
chromatography overlay assay of verotoxin 
binding to glycolipids Gb, (lane l), Gg, 
(gaINA@ -4galpl-4glc ceramide; lane 2), 
Gb, (lane 3) and aminoGb, (lane 4). (a) 
Orcinol detection of all lipids. (b) VT1 , (c) 
Vl2, (d) Vl2c and (e) Vl2e binding. 
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Figure 2 
Binding of verotoxins to glycolipids. (a) VT1 , 
(b) Vl2, (c) VT2c and (d) Vl2e were tested 
for binding to Gbs (M), Gb, (A) and 
aminoGb, (Cl) in microtitre plate format. 
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of the glucose-ceramide linkage of aminoGb4 (Fig. 3a) is 
conformer 2 according to earlier molecular mechanics 
calculations [38]. This conformation, unlike the other two 
favoured conformations for the glcpl-lceramide linkage 
(numbers 5 and 6), allows the hydrocarbon chains of the 
ceramide to extend from the protein with an orientation 
compatible with packing in a lipid bilayer. 
Modelling of cleft site complexes of verotoxins with Gb, 
The docking of Gb, in the cleft site of VT1 [35] was 
further refined with energy minimizations in the presence 
of a shell of explicit water molecules (Fig. 3d). Similar 
calculations were performed for the complexes of Gb, with 
VT2 and VTZe (Fig. 4), which had been modelled by 
homology to the VT1 B-subunit crystal structure. In 
addition to the hydrogen bonds ThrZlOH to gala06 and 
galp60H to Asp17 in VTl, reported in our preliminary 
studies [35], the galor60H is also hydrogen bonded to the 
side chain of Glu28 (which is reoriented from the crystal 
coordinates), and gal&OH is hydrogen bonded to Aspl7, 
galo40H to Lysl3 and galp20H to Gly60 (Table 1). 
Corresponding hydrogen bonds were also observed in 
complexes of VTZ, VT& and VT2e with Gb,, except that 
the hydrogen bond at gaQ360H is considerably weakened 
by the replacement of Asp16 by Asn in VT& (Table 1). 
The axially oriented 4-hydroxyl group of the gala points 
into a polar pocket lined by the side-chain carbonyl of 
Asnl5, the NH,+ group of Lysl3 and the carboxyl group of 
Glu65 of the adjacent B-subunit (Fig. 3d). The gala40H 
group is within hydrogen bonding distance of all these 
three groups, but in VT1 these hydrogen bonds tend to be 
weak. This is because the carboxyl group of Glu65 has a 
restricted mobility and is shielded as a hydrogen bond 
acceptor because of close interactions (a hydrogen bond and 
ionic contacts) with Lysl3 and the amino-terminal Thrl of 
the adjacent subunit. For VT2 and VT&, in which Thrl is 
missing, the calculations predict significantly stronger 
hydrogen bonds for the gala40 group (with Lys 12 and 
Glu64). In the VTl-Gb, complex, the gala30 group is not 
involved in hydrogen bonding with the protein. The 
adjacent carboxyl group of Glu65 is not available as an 
acceptor due to the interaction with Thrl mentioned 
above. However, in VT2 and VT& the galaSOH can 
establish a strong hydrogen bond with the corresponding 
carboxyl group of Glu64. In the VTZe-Gb3 complex, a 
hydrogen bond in the opposite direction (from the side 
chain amide nitrogen of Gln64 to gala30) is predicted. 
The glcp60 was also within hydrogen-bonding distance 
of the carbonyl oxygen of Gly60 in VT1 and the 
corresponding Gly59 in the VT&. This hydrogen bond is 
weak and donation can either take place to surrounding 
water (as in the VTl-Gb, complex) or to glcl305. In VT2 
and VTZc, the glcl360H preferentially establishes a 
hydrogen bond to the carboxyl group of Glu57. 
Two intramolecular hydrogen bonds in the Gb, trisacch- 
aride were also observed in all the complexes: glcp30H to 
gall350 and galp30H to galaSO. A hydrogen bond 
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Figure 3 
AminoGb4 and Gb, docked in site I (cleft site) of VT1 . (a) Side view of 
aminoGb, docked in site I. (b) Schematic of interactions of aminoGb, 
in site I. Dashed arrows indicate the calculated hydrogen bonds of the 
complex, weak hydrogen bonds are shown as dotted lines and non- 
polar van der Waals contacts are shown as green spikes. The diagram 
was created using the Ligploff HBplus programs [70]. (c) The VT1 B- 
subunit-aminoGb4 complex in (a) rotated 90” to show the membrane- 
facing surface of the toxin. The salt bridge in the complex from the 
galNHs+ to Asp1 6 reorients the Asp1 6 side chain leading to the loss 
of the Asp1 6-Arg33 salt bridge, present in the crystal structure of the 
VT1 B-subunit pentamer. (d) Side view of Gb, docked in site I. In (a), 
(c) and (d) the protein is shown with space-filling atoms, as is the 
glycolipid in (c). A  ball and stick representation is used for the 
glycolipid in (a) and (d). Carbon atoms of the fourth B-subunit (left) are 
shown in black; those of the third subunit are in green. The carbons of 
Phe30 and Asp1 7 are orange. Non-polar hydrogens in the protein 
have been omitted. Hydrogen bonds are indicated with dashed white 
lines. The subunit surface which faces the target cell membrane is 
directed down. For an overview of the receptor binding sites see the 
supplementary material and [351. 
between galP30H and gala60 was formed in all the There is extensive hydrophobic contact between the hydro- 
complexes except VTZe-Gb, and VTZe-Gb4. Table 1 phobic face of the galP and the side chain of Phe30 in the 
lists the hydrogen bonds for all site I complexes studied, complexes of VT1 with Gb, and aminoGb4 (Fig. 3). In the 
with the calculated donor-acceptor distances. case of the VT2 complexes (Figs 4, S), a similar hydrophobic 
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Table 1 
Hydrogen bonds in the minimized verotoxin-glycolipid complexes. 
Complex VT1 -aminoGb4 VT1 -Gb, VT2,Vl2c-Gb, VTPe-Gbs VT2e-Gb, 
Donor 
- 
Acceptor Donor-acceptor Donor-acce tor 
distance (A) 
Donor-acceptor 
distance (A) 
Donor-acceptor 
distance (A) distance ( 1 ) 
Gin64 HE1 galNAc40 
Gln64 HE2 galNAc50 
galNl3 2NH Asp1 6 OD2 
galNf3 30H Asp1 6 OD2 
Thrl NH galN 40 
galN640 Thrl OH 
gala 20H Asp1 6b (Glul5*) OD2 
gala 30H Glu65(64*) OEl 
gala 40H Glu65(64*) OEl 
Gln64 HE2 gala 30 
Gln64 HE2 gala 40 
Lysl3(12*) NZH gala 40 
Lysl3(12*) NZH galu 60 
Thr21(20*) OH gala 60 
gala 60H Glu28(27’)OE2 
galf3 20H Gly60(59*)0 
gall3 60H Asp1 6 (Glul5’) 002 
Trp29 NE1 H galf3 60 
g1cp 60H Gly60(59*) 0 
g1cp 60H Glu57 OEl 
na 
2% 
2.9 
2.0 
2.8 
2.9 
2%’ 
na 
2% 
2.8 
2.7 
2.8 
2:;3 
na 
na 
na 
na 
na 
na 
El 
2.7d 
na 
2% 
2.8 
2.7 
2.9 
2.6 
na 
e 
na 
na 
na 
na 
na 
na 
2% 
2.8 
e 
na 
;.i 
2.8 
2.7 
3.0 
2.7c 
2.Qd 
e 
2.7 
na 
na 
na 
na 
na 
2:“9 
na 
2”.“9 
3.2 
2.8 
2.7 
2.9 
2.9 
3.0 
2.7 
e 
2.0 
na 
3.1 
2.8 
na 
na 
na 
2:“9 
na 
na 
- 
3.3 
2.7 
2.8 
2.9 
2.9 
2.6 
e 
2.9 
na 
Intra-saccharide bonds 
galf3 30H 
gall3 30H 
glcl3 30H 
galNAc 30H 
galoc 60 2.8 2.8 2.8 
galci 50 3.1 3.1 2.4 
gal6 50 3.0 2.7 2.8 
galNAc 70 na na na 
2.9 2.9 
2.7 3.0 
na 2.7 
%uperimposed H-bond/salt bridge. 
bVTl numbering used. Asterisk refers to equivalent amino acid in VT2’s. 
CMissing in VT2c. 
surface is provided by Trp29. Although this side chain is 
larger in size, the indole is less able to align efficiently with 
the galB, probably due to the fact that the bulkier indole is 
more restricted by surrounding side chains of the protein. 
Modelling of the VT2e-Gb, complex 
Energy minimizations of Gb, within the cleft site of VTZe 
(Fig. 5) showed that the terminal galNAcP residue can be 
favourably accommodated in contact with Glu15 and the 
side chain of Gln64 of the adjacent subunit. A strong 
hydrogen bond is seen between the side-chain amide 
nitrogen of Gln64 and the 40 of the galNAc. Furthermore, 
the acetamido group of the galNAc establishes van der 
Waals contacts in a shallow trough between the side chains 
of Asp16 and Glu1.5. The hydrogen bond interactions of the 
ct- and B-galactoses are maintained as compared to the 
VTZe-Gb3 complex (Table 1). The $/rJ torsional angles of 
the glycosidic linkages of Gb, in the complex with VTZe are 
listed in Table 2. For the globotriaose moiety, the agreement 
with the other complexes is <*lo”, while the galNAcBl- 
3galcx linkage shows a moderate (2.5”) deviation from the 
+/+ values of the VTl-aminoGb4 complex and the 
corresponding unbound tetrasaccharide. The +/+ angles for 
the galNAcBl-3galo linkage in the VTZe-Gb4 complex are 
still within a favourable range, however, since this linkage 
characteristically has a shallow potential-energy well [39]. 
dWeak H-bond due to suboptimal angle geometry. 
eObserved in minimizations and/or MD without explicit water. 
na, not applicable 
Binding studies with deoxy Gb, analogues 
In parallel with the modelling studies we assayed the 
binding of verotoxins to monodeoxy Gb, analogues in 
which specific hydroxyl groups of the terminal and 
penultimate galactose residues have been removed. 
Binding was monitored both by thin-layer chromatography 
Table 2 
Calculated minimum energy conformations of the saccharide 
moieties of the glycolipid receptors Gb,, aminoGb, and Gb, in 
the unbound state and complexed (at site I) with verotoxins. 
Glycosidic l inkages (+/IJJ)~ 
Molecules Program galN(Ac)pl-3gala gala1 -4galp gal61 -4glcp 
Gb, free HSEAb -39”/-14” 5E”100 
Gbs-VT1 AMBERC -40°1-40 55Ol-5O 
Gbs-VT2 AMBERG -41”1-1” 337-l 7” 
Gbs-VTPe AMBERC -30°/-30 46°1-100 
aminoGb, free HSEAb 56’11’ -39°/-140 57a/-loo 
aminoGb, free AMBERC 62”/-19” -36’1-6’ 55’1-6” 
aminoGb,-VT1 AMBERC 49’1-3’ -37°/-50 4o”/1 o” 
Gb, free AMBERC 50°/-120 -35’12” 60°110 
Gb,-VTPe AMBERG 35”/-29” -28”ll o 40Ol4” 
aThe $I+ torsion angles are defined as $I = Hl -Cl -01 Cx, I+ = Cl - 
01 Cx-Hx. For a complete list and interaction energies see the 
supplementary material. 
bHSEA calculation using GESA. 
CAmber-potentials using the Discover program (E = 1 with explicit water). 
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Figure 4 
Gb, docked into site I of (a) VT2 and (b) VT2e. In the Vl2-Gbs complex, group of Glu64 in the adjacent subunit. In the case of VTSe-Gbs, Gin64 
the cu-galactose makes a strong H-bond through 03 with the carboxyl donates an H-bond to gala30. The representation is as for Figure 3a. 
overlay for VT1 (Fig. 6) and binding within a phospholipid 
matrix in microtitre wells (Fig. 7) for all VTs. Although VT1 
binding to the parent synthetic analogue as assayed by thin- 
layer chromatography overlay is considerably less than for 
natural Gb,, as we have previously noted [33], we were still 
able to observe the effect of deoxysugar substitution. The 
hydroxyl requirement for VT1 was in reasonable agreement 
with that determined by receptor binding in the microtitre 
phospholipid matrix which was used for quantitative 
assessment. All hydroxyls within the galabiose are required 
for full binding. The reduction in binding following 
individual hydroxyl deletions was: for VTl, 6” and 6’ > 2’ > 
4” > 2” > 3’ and 3” > Gb,; for VTZ, 6”, 6’, 4” and 3” > 2’ > 2” 7 
3’ r Gb,; for VTZc, 6” and 4” > 2’ and 3” 7 2” and 6’ 77 3’ 7 
Gb,; and for VTZe, 6”, 6’ and 3” > 3’ and 2’ > 2” > 4” 7 Gb,. 
The patterns of binding of VTl, VTZ, VT2c and VTZe to 
these deoxy Gb, analogues are clearly distinguishable 
(Fig. 7). The primary differences are: the more significant 
role of the 4”OH in VT2 and VT2c binding, the 
requirement of the 3”OH for the binding of VT2s 
(particularly VT2e) but not VTl, the greater significance 
of the 3’OH for VT2e binding and the relative lack of 
effect of 6’OH removal on VT2c binding. 
Docking in site II 
The Gb, oligosaccharide can also be favourably docked 
into site II [35] of VT1 (Fig. 8) using an automatic program 
[40,41] which detects complementarity in shape between 
receptor and ligand. Several possible docking positions 
were identified in site II, but only a few permit suitable 
orientation of the ceramide for inclusion in a membrane 
bilayer, considering the favoured conformations of the 
glcpl+lceramide linkage [42]. Of these few, the one with 
the best van der Waals contacts was subjected to energy 
minimization. Several hydrogen bonds that involve the 
galabiose moiety (Ser64NH+galo160, galo60H+Lys53, 
gala30H+Asp16 and galpZOH+Asn32) were found after 
minimization of this complex. As shown in Figure 8, this 
orientation of the saccharide in site II is compatible with 
bilayer packing of the ceramide moiety when adopting 
conformer 6 for the glcPl+lceramide linkage. 
Discussion 
AminoGb, binding and docking model 
We have identified a new glycolipid receptor for 
verotoxins in vitro, which is at least as active as any 
receptor species previously described for any member of 
the verotoxin family. By thin-layer chromatography 
overlay, aminoGb4 is the preferred receptor for all 
verotoxins (Fig. 1). Although the physiological relevance 
of this binding has yet to be established, toxin recognition 
of aminoGb4 in vitro provides an important insight into 
the structural basis of the specificity of the different 
verotoxins for different receptors. We have previously 
speculated that there are two potential Gbs-binding sites 
per B-subunit monomer [35]. The present studies show 
that, whereas it has not been possible to accommodate 
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Figure 5 
Gb, docked into site I of VT2e. Note that the galNAc6 is in proximity to the 
side chain of Gln64 of the adjacent B subunit. The NAc group is 
accommodated in a trough between Asp1 6 and Glu15. A hydrogen bond 
between the galNAcf330H and the oxygen of the NAc group is indicated 
by a dashed line. 
aminoGb4 in the second site irrespective of the 
conformation of the saccharide-ceramide linkage, it can 
be effectively docked in site I, the ‘cleft’ site (Fig 3a). 
This can be explained by the formation of a salt bridge 
between the NH,+ group of aminoGb4 and the carboxyl 
group of Asp16 and additional electrostatic interactions 
with the carboxyl groups of Asp17 and Asp18 that, 
together with Aspl6, generate a focus of negative 
potential in this region of site I (see Supplementary 
material). The charge of the amino group and the partial 
positive charges across the CX- and P-galactoses, provide a 
continuous positive surface on the face of the terminal 
trisaccharide that is next to the toxin to complement the 
negative charge within the cleft site (see Supplementary 
material). Preliminary studies indicate that complexes of 
aminoGb4 with site I of the other verotoxins are stabilized 
by similar electrostatic interactions. 
As shown in Table 2, only minor conformational changes of 
the C$/IJJ angles, as compared to the minimum energy 
conformation in the free state, are required to fit the 
saccharide moiety of aminoGb4 into site I of VTl. The 
galal-4galp linkage, which is known to be the most 
restricted of the three glycosidic linkages, only has to 
undergo changes of a few degrees. The required changes in 
$/$ values for the galpl-4glcl3 and the galNpl-3galo 
linkages are < 20”. This can be achieved without significant 
energy penalties, since both of these types of linkages, 
particularly the latter, have considerable flexibility [39]. 
The fact that N-dimethylated aminoGb4 is efficiently 
bound indicates that additional methyl groups can be 
accommodated without perturbing the structure of the 
complex. This is consistent with a model in which the 
amino function of the galactosamine is located at the 
surface of the Aspl6-Asp18 loop, allowing interaction 
with a more bulky positively charged group. The inability 
of VT1 to bind Gb, is probably a result of electrostatic 
repulsion between the carbonyl oxygen of the NAc group 
(missing in aminoGb4) and the carboxyl group of Asplb. 
Deoxy sugar analogue binding: confirmation of the cleft 
site (site I) model 
The data on the binding of the deoxy Gb, analogues to all 
the verotoxins (Fig. 7) are in excellent agreement with 
Figure 6 
(a) 
W 
123456789 
lz51-VT1 binding to deoxy Gb, bisalkyl analogues. (a) Orcinol 
detection of glycolipids by thin-layer chromatography overlay. (b) VT1 
binding. Lanes 1) Gb,, Gb, and Forssman, 2) parent Gb, bisalkyl 
analogue, 3) 2” deoxy, 4) 3” deoxy, 5) 4” deoxy, 6) 6” deoxy, 7) 2’ 
deoxy, 8) 3’deoxy, and 9) 6’ deoxy analogues. Sample size was 2 ug for 
each glycolipid. 
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Figure 7 
:a) 30 1 
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Microtitre binding assay of deoxyGbs analogues by 1251-labelled- to the deoxy analogues were: for gala6 deoxy Gb, 3 o/o, <l o/o, <l O/o, 
verotoxins. (a) VT1 , (b) VT2, (c) VT2c and (d) VT2e were assayed for <l %; for gala4 deoxy Gb, 31 ‘J/o, <l %, <l %, 51 O/o; for gala3 
binding to Gbs (control: l ), 2” deoxy Gbs (0), 3” deoxy Gb, (A), 4” deoxy Gb, 76 %, 5 %, 12 %, <l %; for gala2 deoxy Gb, 41 010, 45 010, 
deoxy Gb, (m), 6” deoxy Gbs (O), 2’ deoxy Gbs (--O--), 3’ deoxy Gbs 23 o/o, 26 o/o; for gal66 deoxy Gb, <l O/o, 2 O/o, 30 o/o, <l o/o; for gal63 
(--A--) and 6’ deoxy Gb, (-0). Data for deoxy analogues of the deoxy Gb, 66 %, 75 O/o, 71 O/o, 10 %; for gal62 deoxy Gb, 26 010, 
6-galactose are shown as dotted lines. In comparison to the parent 26 O/o, 7 ‘J/o, 13 O/o. (Ratios were determined in the presence of 
unmodified species, percentage binding of VTl, VT2, VT2c or VT2e 100 nmole of glycolipid). 
hydrogen bond predictions from the docking comp- 
utations. Previous studies of monodeoxygalabioses indi- 
cate that the overall conformation of the disaccharide is 
not altered by such modification [43]. The requirement 
for the 6”OH is consistent with the prediction that it forms 
hydrogen bonds with Thdl and Glu28, and the 6’OH 
requirement for VTl, VT2 and VT2e binding is consis- 
tent with a hydrogen bond to Asp17 (VT1 numbering). 
The 4”OH requirement for VT2 and VT& binding can be 
explained by the predicted hydrogen bond to the carboxyl 
group of Glu64. In VTl, however, the corresponding 
residue, Glu6.5, is partially buried and interacts with the 
amino-terminal Thrl, explaining the reduced requirement 
for the gala40 (Fig. 7). Glu65 is beyond hydrogen-bond 
distance of gala30 in VT1 (Fig. 3d) and this hydroxyl is 
less important for VT1 binding to Gb, as opposed to the 
other toxins (Fig. 7). In VT2 and VT%, however, the lack 
of restriction by Thrl and Pro2 would probably allow the 
exposed carboxyl group of the corresponding residue, 
Glu64, to hydrogen bond with gala30 and galo40, thus 
explaining the selective requirement for these hydroxyls 
for receptor binding by these toxins (Fig. 7). In the 
VTZe-Gb3 complex these carboxyl hydrogen bonds are 
lost due to the substitution Glu64+Gln, but a hydrogen 
bond in the opposite direction, from the side chain amide 
nitrogen to galo30, is formed. This would explain the 
requirement for the gala30H for VTZe binding (Fig. 7). 
In the minimized complexes, the galP30H forms intra- 
molecular hydrogen bonds with 05 (and 06) of gala, 
Figure 8 
Gbs conformer 6 docked in site II of VT1 . The terminal a-galactose 
forms the following hydrogen bonds with the toxin: Ser64NH+galo60, 
gala60H+Lys530, gala30H+Aspl6. Only one hydrogen bond to 
the 6-galactose (gal620H+Asn320Dl) is observed. 
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rather than interacting with the protein (Table 1). An 
intramolecular hydrogen bond between galP3OH and 
gala50 has also been observed in the crystal structure of 
galabiose [44]. The intrasaccharide hydrogen bonds are 
likely to stabilize the conformation of the galal-4galp 
linkage and thus favour interactions of the galabiose 
moiety with the protein. This may explain the reduction 
in binding seen for the 3’deoxy analogue (Fig. 7). 
Comparison of Gb, docking in site I of Wl, 2,2c and 2e 
The modelling of the site I complexes indicates that 
Asp17 is a crucial hydrogen bond acceptor for galp60H 
and gal&OH. This is important, since the corresponding 
residue in VTZc (which is of -1000 fold lower cytotoxicity 
and has a reduced Gb, binding affinity as compared to 
VT1 [45,46]) is asparagine (Asn16). Mutation of this Asn in 
VT& to Asp results in a dramatic increase in cytotoxicity 
[47], probably because the affinity of Gb, binding 
increases due to formation of a hydrogen bond between 
galp60H and the carboxyl group of Aspl6. Consistent 
with this model, the 6’ deoxy sugar substitution had 
markedly less effect on the binding of VT& than of VTl, 
VT2 or VTZe (Fig. 7). It is also possible that the sub- 
stitution Asplb+Asn in VTZc allows closer proximity to 
the n-system of Trp29, restricting cleft site access. 
The amino acid residues forming site I in the verotoxins 
are highly conserved within the verotoxin family. This 
region of conservation was noted in the original crystallo- 
graphic studies and was therefore suggested as a potential 
receptor-binding site [30]. Moreover, the sequence for- 
ming site I in the verotoxins shows extensive similarity 
with CD19, which binds globo-series carbohydrates 
(globotriaose and globotetraose) [23]. The o12-interferon 
receptor also shows amino acid similarity with VT site I 
and binds globo-series glycosphingolipids [Z]. The 
existence of these sequence similarities among proteins 
which all recognize glycolipids of the globo series is in 
agreement with the proposed role of site I as a binding 
site for galol-4gal-containing saccharides. 
Comparison of the model with mutational analyses 
Glu6.5 in VT1 has been mutated to Gln [48], resulting in 
complete loss of receptor recognition. This observation is 
consistent with our modelling, which indicates a 
gala40-tGlu6.5 hydrogen bond and predicts the loss of 
this hydrogen bond on substitution with Gln in VT1 (data 
not shown). Mutation of the equivalent residue in VTZe 
(Gln64+Glu) [49] was involved in the alteration of 
binding specificity from Gb, + Gb, to Gb, alone. 
Mutation of Phe30-tAla results in a loss of Gb, binding 
[SO], consistent with the alignment of the hydrophobic 
side of the P-galactose with the phenyl ring in the cleft 
site. Mutation of Gly59 in VT2 (or Gly60 in VTl) has 
been shown to result in >50 %  loss of receptor binding 
[Sl], which would be consistent with involvement of this 
residue in site I (see Table 1). Loss of Gb, binding after 
mutation of Arg33 [Sl] is more consistent with binding at 
site II, although Arg33 is involved in a salt bridge to Asp16 
[31] in site I of VT1 (Fig. 3~). Loss of receptor binding 
following removal of the carboxy-terminal four amino 
acids in VT2 [52] is also consistent with site I usage. 
Furthermore, the loss of Gb, binding following the double 
mutation Asplb+His, Aspl7+His in VT1 [48] and the 
increased potency of VT& after mutation of Asnlb-tAsp 
[47] are consistent with the proposed involvement of 
Asp16 and Asp17 in site I. 
Model for recognition of Gb, by W2e: crucial role of Gln64 
VTZe is the only toxin that binds Gb,, while all the VTs 
bind Gb, and aminoGb4 (Fig. 1). Several amino acid 
substitutions in VTZe within the cleft binding site, as 
described above, explain this difference in binding 
specificity. In VTl, the pocket between the side chains of 
Asp16 and Asp17 is not sufficient to accommodate the 
acetamido group of Gb,. In particular, the close approach 
of the oxygen of the NAc group towards the carboxyl 
group of Asp16 would disfavour Gb, interaction with VTl. 
This explanation is consistent with the observation that 
mutation of Asp18 to Asn in VT1 allows Gb, binding [49]. 
In this mutant, the mutual electrostatic repulsion within 
the Aspl6-Asp18 loop is reduced, allowing the carboxyl 
group of Asp16 to reorient and thus avoid interference 
with the acetamido group. The side chain of Gln64 in 
VTZe also has a capacity to hydrogen bond with the 
carboxyl group of Glu15, thus stabilizing a trough between 
the side chains of Glu15 and Asp16 that accommodates 
the NAc group of Gb, (Fig. 6). 
In the modelled complexes of VT2 and VT& with Gb,, 
the 3”OH group donates a strong hydrogen bond to the 
carboxyl group of Glu64. In the case of Gb,, the 3”OH is 
blocked by the galNAc substitution and cannot act as an 
H-donor to Glu64. The 01 and 05 atoms of the added 
galNAc would instead cause steric and electrostatic 
repulsion with the carboxyl group of Glu64. This is a 
likely explanation for the lack of Gb, binding by VT2 and 
VT&. In VTZe, however, Glu64 is replaced by a 
glutamine residue, which stabilizes the VTZe-Gb4 
complex by donating a hydrogen bond to the galNAc40 
and potentially also to the 01 and 05 oxygens of this 
moiety. This model of the VTZe-Gb4 complex is 
consistent with the fact that GT3, a double mutant of 
VTZe (Gln64+Glu, Lys66jGln) [49], does not bind Gb,, 
though Gb, binding is retained. Neither mutation alone 
affected Gb, binding. The lack of effect of the single 
mutation Lys66WGln is consistent with the model since 
residue 66 makes no direct contact with the Gb, 
saccharide bound in the cleft site. The fact that the single 
mutation Gln64+Glu in VTZe does not block binding of 
galNAc (by interactions similar to those discussed for VT2 
and VT&) can be explained by the attraction of the Glu64 
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side chain to the adjacent positive region formed 
by Lys66, Lysl2 and the amino terminus (Alal). In 
the double mutant GT3, the substitution Lys66+Gln 
decreases this attraction and thus increases the propensity 
of the side chain of Glu64 to extend and interfere with 
Gb, binding. Validation of this interpretation must await 
the availability of quantitative binding data and crystal 
structures of VTZe and its mutants. 
Most of the interactions which stabilize the VTZe-Gb4 
complex are contained within a single B-subunit monomer. 
Only about 10 %  of the interaction energy is due to the 
adjacent B-subunit. Residues in the carboxyl terminus of 
the adjacent B-subunit do, however, prevent the binding 
of Gb, by VT2 and VT2c. Therefore, we would predict 
that if monomeric VT2 B-subunits (VTZ, 2c or 2e) were 
produced, these would also bind Gb,. This possibility is 
further supported by the finding that CD19, which has an 
amino-terminal extracellular domain that shows sequence 
similarity to the VT B-subunit [23], does not contain 
residues equivalent to the extramonomeric sequences 
involved in verotoxin site I-Gb, binding [24] and binds 
both globotriaose and globotetraose oligosaccharides [23]. 
Receptor binding in site II 
Previous calculations with the GRID program indicated a 
favourable second binding site (site II) for the Gb, 
oligosaccharide in the region of Gly62, Asn32 and Phe30 
[35], but a different glycolipid conformer (number 6 [38]) 
was required as compared to site I. It was speculated that 
site II might function in Gb, binding by VT2c and VTZ, 
which show a preference for Gb, containing Cl8 fatty 
acids, while VT1 prefers Gb, with longer fatty acid chains 
[36,53]. If the fatty acid chain length affects the glycolipid 
conformation, the resultant binding in different sites 
would explain the relative lack of inhibition of VT1 
binding by VT2c and vice versa [36]. 
The present studies, using an automatic docking program, 
confirm that Gb, conformer 6 can be accommodated in site 
II (Fig. 8). Several fits were found; the most favourable is 
shown in Figure 8. In this position, the gala30 is oriented 
towards the side chain of Aspl6. Modelling indicates that 
an additional galNP or galNAcP residue linked to the 
3-position of the ol-galactose of Gb, in site II would 
essentially extend away from the protein surface, devoid of 
favourable contacts with the toxin. In contrast, the site I 
complexes calculated for VTl-aminoGb4 and VTZe-Gb4 
allow a number of favourable interactions for the terminal 
amino sugar with the protein. We thus conclude that 
aminoGb4 and Gb, are very likely to bind only in site I. 
The significance of Gb, binding in site II of VT2c or any 
other verotoxin cannot be inferred from our present study. 
Since our site II model is not in agreement with the 
binding data for deoxy analogues of Gb,, and none of the 
synthetic analogues studied preferentially bind VTZc, it is 
likely that the VT2 and VT2c binding presently observed is 
restricted to the cleft site, as for VTl. Our calculations 
indicate that the interaction energy of the site II VTl-Gb, 
complex is only 50 %  of that calculated for site I. Moreover, 
the model of binding at site II cannot readily explain the 
importance of Phe30 (in VTl) and Asp16 (in VT2) for Gb, 
binding suggested by mutational studies [47,50]. 
It is of interest, however, to note that the modelling 
suggests that Gb, binding in site II would not interfere 
with Gb, binding in site I. It may thus be speculated that, 
due to the effects of multivalency, even partial occupancy 
of site II would increase the overall affinity of the 
interaction. The recognition of different conformers by 
the two sites might ensure efficient receptor recognition 
in a variety of cell membranes with different lipid 
compositions. Further studies are required to establish the 
relative significance of site I and site II in different 
verotoxins. These studies might also shed light on a series 
of poorly understood factors affecting the affinity of 
verotoxin-GbJ interactions, such as fatty-acid chain length 
of the receptor [36,53,54] and the matrix lipids [SS], 
receptor concentration in the bilayer [33] and the method 
of immobilization of the receptor glycolipid [33,55]. An 
understanding of these phenomena, which apparently 
relate to the steric presentation of the saccharide epitope 
[56], is important for the design of high affinity inhibitors 
of VT-Gb, interactions. 
Preliminary X-ray analysis of a cocrystal of VT1 
B-subunits with globotriaose oligosaccharide (R. Read, 
personal communication) indicate density primarily in the 
region of site II and in the region of Trp34. Density due to 
saccharide was later also resolved in the region of site I 
(Ling, H., Boodhoo, A., Armstrong, G.D., Brunton, J.L. & 
Read, R.J., poster W127, Proceedings of the American 
Crystallographic Association Annual Meeting, Montreal, 
Quebec, Canada, July 1995). Although these data are only 
in partial agreement with our modelling, they do support 
the proposal of two binding sites (sites I and II). It is 
possible that cocrystallization with the oligosaccharide 
does not reproduce the steric presentation that applies 
when the saccharide is presented on the surface of a lipid 
bilayer, and is coupled to a lipid moiety anchored within 
the bilayer. Thus it is our contention that molecular 
modelling combined with detailed binding studies is 
currently the preferred method for localization of the 
glycolipid binding site in this system. 
Significance 
The binding of verotoxin to globotriaosyl ceramide on 
human endothelial cells is the basis for the vascular 
pathology of hemorrhagic colitis and hemolytic uremic 
syndrome (HUS). HUS results in significant pediatric 
mortality and long term renal insufficiency. The model 
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we present here for verotoxin-Gb3 interactions provides 
a framework for the rational design of novel high 
affinity soluble inhibitors with therapeutic potential. 
The verotoxin-Gbg interaction is an intriguing example 
of protein-carbohydrate recognition. Although vero- 
toxins are galabiose-binding ligands, high affinity 
interactions only occur in the context of glycolipid 
structures. Since glycolipids and proteins cannot be 
easily co-crystallized or studied by NMR due to 
solubility problems, molecular modelling is an important 
tool for the study of this receptor-ligand interaction. 
We have precisely defined a region at the cleft between 
adjacent B-subunits as the major Gb, binding site. Our 
binding model predicts the high binding affinity of 
aminoGb+ a new, preferred receptor glycolipid for all 
verotoxins, and explains how amino-acid differences 
found in the carboxyl terminus of VT2e allow Gb, 
binding. Different hydroxyl group requirements in the 
galabiose moiety are demonstrated for the binding of 
each verotoxin and the molecular basis of these 
requirements are explained by our model. 
The model also explains the importance of the lipid 
moiety in VT-Gb, binding, as only one of the possible 
conformations of the sugar-lipid linkage allows efficient 
binding in the proposed ‘cleft site’. We also propose a 
second binding site, which accommodates a different 
conformer. This site may be significant for VT2c 
binding, thus explaining the lack of competition between 
VT1 and VT2c for receptor binding 1361. This suggests 
that under appropriate conditions the B-subunit 
pentamer could have a maximum receptor valency of 
ten, potentially doubling the receptor’s binding capacity. 
Materials and methods 
The neutral glycolipid fraction from human renal tissue was prepared as 
described previously 1571. Gb, and Gb, were separated by silica-gel 
chromatography. Verotoxin-unreactive Gb, was deacetylated by 
aqueous base hydrolysis to give a ceramide tetrasaccharide containing 
a free terminal galactosamine residue (aminoGb,) [37]. VT1 was 
purified from pJLB28 [58], VT2 from R94 [591, VT2c from E3211 [451 
and VT2e from pGTlO0 [491. VT2 and VT2c were purified by Gb, 
affinity chromatography [60]. Affinity purification had no effect on 
glycolipid-receptor binding specificity. 
Deoxy Gb, analogues 
Deoxy derivatives of the terminal and penultimate sugars of a synthetic 
Gb, analogue containing globotriaose in anomeric linkage to a 
bis-C16-alkyl sulfone aglycone (compound B5 in Boyd et al. 1331) 
were synthesized as described [61,621. The deoxy compounds 
were standardized by benzoylation-HPLC analysis [57] and the 
glycosphingolipids were standardized using a sphingosine assay [631. 
Verotoxin-glycolipid binding 
The thin-layer chromatography overlay assay of 1251-VT [46,64] binding 
was performed as described [65,66]. Quantitative analysis of receptor 
function in a phospholipid matrix was carried out in microtitre plates 
using a modification of our previously described procedure [33,36]. 
Plates were coated with 50 ul of methanol containing 50 ng phos- 
phatidyl choline, 25 ng cholesterol and 0, 5, 10, or 100 ng receptor 
glycolipid and allowed to dry overnight at room temperature. Before 
binding, plates were blocked with 0.5 % BSA in phosphate buffered 
saline (PBS) for 1 h at room temperature and washed three times with 
PBS. 1251-labelled toxin was added to wells in triplicate (100 ng per 
well in 100 ~1 PBS containing 0.5 % BSA) and incubated for 1 h at 
room temperature. After extensive washing, the wells were cut out and 
bound radioactivity counted. 
Modeling 
All the calculations of VT1 binding were performed using the coord- 
inates from the crystal structure of the pentamer of B-subunits of VT1 
(301. The B-subunits of VT2, VT2c and VT2e were homology modelled 
starting from VT1 B. The oligomer binding (OB) fold motif present in 
VT1 has been observed in a number of oligosaccharideloligonucleotide 
binding proteins (see [67] for review). Comparative studies 1671 have 
shown that the barrel-helix frameworks of these structures are 
superimposable with root-mean square deviations of 1.4-2.2 A, 
although the amino-acid sequences are totally unrelated. This indicates 
that the OB fold in the verotoxins is quite stable and we thus did not 
expect any significant folding differences between VT1 and the VT2s, 
which all have a sequence homology of 62-65 % with VT1 In particular, 
strands 1-3, which are involved in site I, only show conservative 
substitutions when comparing VT2, VT2c and VT2e with VTl. For these 
reasons the procedure for modelling the VT2s was limited to side chain 
substitution followed by energy minimizations (Insight II/Discover with 
AMBER parameters). This was done for a system of two adjacent B- 
subunits (numbers three and four) initially with fixed backbone and 
subsequently with restraints for the backbone. 
The minimum energy conformations of the saccharide moieties of Gbs, 
aminoGb4 and Gb,, respectively, were obtained with the GESA 
program [38]. For the proximal glcpl-1 ceramide linkage and the lipid 
moiety, favoured conformations were adopted from previous studies 
with molecular mechanics (MM3) [381. Electrostatic surface properties 
of VT1 and of aminoGb4 were analyzed using the Delphi program [68]. 
Energy minimizations for the different complexes (VT1 -Gb,, VTS-Gb,, 
VT2c-Gb,, VTPe-Gb,, VTl-aminoGb, and VT2e-Gb,) were per- 
formed on systems consisting of a dimer of B-subunits (numbers three 
and four) and the saccharide moiety of the respective glycolipid. The 
calculations were carried out with the Discover program (Biosym Inc.) 
using the AMBER all-atom parameter set and saccharide parameters 
developed by Homans [69]. The starting orientation of the gala1 -4galf3 
moiety in site I was obtained from previous calculations (351. The 
minimizations were initially performed with a distance-dependent 
dielectric constant (E = 4r) with a fixed peptide backbone. For each 
system several minimizations were carried out with somewhat different 
starting orientations for the saccharide and different conformations for 
the side chains of Glu28 (VT1 numbering) and Gln64 (VT2e). Short 
molecular dynamics (MD) simulations (1 O-l 5 ps) followed by 
minimizations were also performed. The energetically most favourable 
geometry found in these MM and MD runs was subject to energy 
minimization (steepest descent and conjugate gradient) with a 5 A 
shell of explicit water molecules (at E = 1). The restraints for the protein 
were gradually released, maintaining only light tethering for the peptide 
backbone in the final stage. The minimizations were continued until the 
maximum derivative was < 0.001 kcal A-l. 
To locate additional possible binding sites on the B-subunit, an 
automatic docking procedure that detects shape complementarity 
[40,411 was applied. Using this method, the Gb, and aminoGb, 
saccharides were docked with a dimer of B-subunits (numbers three 
and four) of VTl. Elimination of orientations with unfavourable van der 
Waals clashes was performed in the presence of the adjacent two 
subunits (numbers two and five). Typically about 500 orientations were 
obtained. These were manually inspected and assessed in terms of 
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compatibility with the lipid packing of the ceramide, considering the 
three preferred conformers for the ceramide-saccharide linkage [42]. 
Molecular manipulation and display for production of pictures were 
performed with the ChemX program (Chemical Design Ltd, Oxford). 
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